AHA Scientific Sessions 2026 Abstract · Nov 2, 2026
Per- and Polyfluoroalkyl Substances and Blood Pressure in Postmenopausal Women
By Chen W, Qiu C, Yang Z et al.
Background: Postmenopausal women experience elevated cardiovascular disease (CVD) risk and heightened susceptibility to endocrine disruption. Per- and polyfluoroalkyl substances (PFAS) are persistent synthetic chemicals with endocrine-disrupting properties. PFAS have been linked with adverse blood pressure (BP) outcomes. However, longitudinal evidence on associations between PFAS exposure and BP in postmenopausal women is limited. Hypothesis: We hypothesized that PFAS exposure is associated with worsening BP trajectories and that these associations differ by menopausal hormone therapy (MHT) use and time since menopause. Methods: We included 641 women (mean ± SD age: 60.6 ± 6.9 years) participating in the Early versus Late Intervention Trial with Estradiol, who were randomized to MHT or placebo within strata of time since menopause (early: <6 years; late: ≥10 years), with a median follow-up of 5 years. BP was measured biannually during follow-up. Plasma PFAS concentrations were measured at baseline and 36 months and averaged to index chronic exposure. Linear regression and linear mixed-effects models were used to examine cross-sectional and longitudinal associations of log ₂ -transformed individual PFAS concentrations with BP, adjusting for age, race/ethnicity, education, smoking, body mass index, antihypertensive medication use, and time since menopause. Longitudinal models were additionally adjusted for MHT assignment and baseline BP. Bayesian kernel machine regression was used to evaluate PFAS mixture effects. Results: At baseline, each doubling of linear perfluorooctanoate (n-PFOA) concentration was associated with higher systolic BP [2.2 mmHg (95% CI: 0.9-3.6; p=0.001)], diastolic BP [1.1 mmHg (0.3-1.9; p=0.006)], and pulse pressure (PP) [1.1 mmHg (0.2-2.1; p=0.02)]. Each doubling of perfluorooctane sulfonate (PFOS) concentration was associated with higher systolic BP [1.3 mmHg (0.2-2.3; p=0.02)]. PFAS mixtures were significantly associated with higher systolic and diastolic BP, with n-PFOA contributing the most. During follow-up, neither average concentrations of individual PFAS nor PFAS mixtures were associated with BP trajectories in the overall population, and no significant interactions with MHT assignment were observed. The association between average perfluorononanoate (PFNA) concentration and the rate of PP increase was stronger among early postmenopausal women [0.3 mmHg (0.0-0.6; p=0.05)] than late postmenopausal women [0.2 mmHg (–0.1-0.4; p=0.19); p-interaction=0.04]. Conclusions: PFAS exposure was cross-sectionally associated with higher BP in postmenopausal women, with n-PFOA being the primary contributor. Larger, more diverse longitudinal studies are needed to clarify the effects of PFAS on BP trajectories and to assess PFAS as a potential modifiable environmental risk factor for CVD prevention in postmenopausal women.